Cell-Based Assay Services to Dominate Bioanalytical Testing Services During 2022–2030
According to our new research study on " Bioanalytical Testing Services Market Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis – by Services, Disease Indication, End User, and Geography," the market is expected to grow from US$ 4,641.13 million in 2022 to US$ 10,108.82 million by 2030; it is anticipated to record a CAGR of 10.2% from 2022 to 2030. Key factors driving the bioanalytical testing services market growth are the increasing outsourcing of R&D activities by pharmaceutical companies, and the high demand for analytical testing of biosimilars and biologics. However, challenges in the development and validation of bioanalytical methods hinder market growth.
The bioanalytical testing services market, by service, is segmented into pharmacokinetics, biomarkers, immunogenicity, virology testing, cell-based assays, and others. The cell-based assays segment held the largest market share in 2022. Moreover, the same segment is anticipated to register the highest CAGR of 11.3% during the forecast period. All tests performed on living cells are considered cell-based tests. Cell-based assays can be classified into cell proliferation, reporter genes, cell death, and cell signaling assays. Cell-based assays measure the quantitative effects of therapeutic drugs, DNA, RNA, protein, small molecules, and nanoparticles. The assays are based on disease states, proliferation, cytotoxicity, signaling pathways, and gene expression. In the regulatory environment, cell-based assays are commonly used to determine the biological activity (potency) of the drug product or drug substance, and discover the mechanism of action (MOA). They are also used to perform cytotoxicity testing and early-stage proof-of-principal studies, while in immunogenicity studies, cell-based assays help in determining whether antibodies produced in the patient's body neutralize the drug.
Bioanalytical Testing Services Market, by Region, 2022 (%)
Bioanalytical Testing Services Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Pharmacokinetics, Biomarkers, Immunogenicity, Virology Testing, Cell-based assays, and Others); Disease Indication (Cardiovascular, Neurological Disorders, Metabolic Disorders, Autoimmune Disorders, Respiratory Diseases, Oncology, Sexual Health, Bone Disease, and Others); End User [Pharmaceutical and Biopharmaceutical Companies, Contract Research Organization (CRO), Contract Development And Manufacturing Organization (CDMO), and Others], and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Bioanalytical Testing Services Market Report | Growth & Forecasts to 2030
Download Free Sample
SGS SA, Pharmaron Beijing Co Ltd, Element Materials Technology Group Ltd, CD BioSciences Inc, Charles River Laboratories International Inc, Eurofins Scientific SE, Labcorp Drug Development Inc, Syneos Health Inc, KCAS Bioanalytical and Biomarker Services LLC, ICON Plc, and Intertek Group Plc are among the key companies operating in the bioanalytical testing services market. These companies have implemented both organic strategies (such as launches, expansion, and product approvals) and inorganic strategies (such as product launches, partnerships, and collaborations) to grow in the markets they serve.
The report segments the bioanalytical testing services market as follows:
Based on service, the bioanalytical testing services market is segmented into pharmacokinetics, biomarkers, immunogenicity, virology testing, cell-based assays, and others. The cell-based assays segment held the largest market share in 2022. The same segment is anticipated to register the highest CAGR during 2022-2030. Based on disease indication, the global bioanalytical testing services market is segmented into cardiovascular, neurological disorders (CNS), metabolic disorders, autoimmune disorders, respiratory diseases, oncology, sexual health, bone disease, and others. The oncology segment held the largest market share in 2022; it is anticipated to register the highest CAGR during the forecast period. The bioanalytical testing services market, based on end user, is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations (CRO), contract development and manufacturing organizations (CDMO), and others. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2022, and the same segment is anticipated to register the highest CAGR during the forecast period. In terms of geography, the bioanalytical testing services market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com